A British travel photographer has revealed the ultimate way to fly—on an $85,000 cargo plane ticket to Antarctica. Alex Stead ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After the best two-year stretch for the S&P 500 (^GSPC) since the late 1990s, few on Wall Street are calling for an end to the bull market run, and this optimism serves as the key throughline in ...

In the kitchen of her South St. Paul home, Abigail Turner prepares the insulin she uses to manage her type 1 diabetes last February. Minnesota announced a final settlement Monday with the last of ...

During her first briefing on Tuesday afternoon, White House press secretary Karoline Leavitt announced the creation of a dedicated seating section for “new media” journalists and said the ...

ST. PAUL (Valley News Live) - Attorney General Keith Ellison announced a settlement with Novo Nordisk that guarantees that all Minnesotans, with or without insurance, can buy Novo Nordisk’s ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

(ABC 6 News) – On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let’s Minnesotans buy its insulin products for $35 per month. For the next five years ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned to the trickier task of finding a way to lose fat while retaining muscle.